GLOW combines two of the most studied regenerative peptides in a single presentation. BPC-157 contributes an angiogenic and soft-tissue remodelling profile drawn from a large preclinical literature; GHK-Cu contributes a copper-delivery and matrix-signalling profile with the strongest supporting evidence of the two, largely from topical dermatological research. The combination is positioned for practitioners working at the intersection of aesthetic and regenerative medicine. As with the individual components, the combination itself has not been studied in controlled human trials, and no interaction or synergy data exist. Practitioners choosing a fixed combination should be satisfied that both components are individually appropriate for the patient, since the ratio cannot be adjusted independently.
Active Compound: BPC-157 5 mg + GHK-Cu 50 mg (combination)
Permitted Claim GuidelinesA combination of two widely studied regenerative peptides. Used under practitioner supervision. The combination has not been evaluated in clinical trials.
Mechanism of ActionDual mechanism. BPC-157 promotes VEGFR2-mediated angiogenesis and organised granulation tissue formation. GHK-Cu acts as a copper carrier, modulating expression of genes governing collagen, elastin and glycosaminoglycan synthesis, and influencing matrix metalloproteinase and TIMP balance during remodelling.
Evidence Grade: D - Combination unstudied; component evidence preclinical to limited-human
Clinical Evidence BaseComponent-level evidence only. GHK-Cu has controlled human data in topical dermatological application. BPC-157 evidence is preclinical. The fixed combination has not been evaluated in any published human or animal study, and no synergy has been demonstrated.
Literature & ReferencesRefer to component literature for BPC-157 and GHK-Cu. No combination-specific literature exists. | Pickart L, Margolina A. Int J Mol Sci, 2018 - GHK-Cu biological actions. | Sikiric P et al. Curr Pharm Des, 2011 - BPC 157 overview.
Safety & PrecautionsCarries the combined precautions of both components. Copper content is the principal consideration: contraindicated in Wilson's disease and used with caution where copper handling may be impaired. Theoretical angiogenic concern in occult malignancy. Not for use in pregnancy or breastfeeding. Injection-site reactions and transient discolouration at the site have been reported with copper peptides.
ContraindicationsWilson's disease or other disorders of copper metabolism; active or suspected malignancy; pregnancy and breastfeeding; known hypersensitivity.
Storage & HandlingStore lyophilised vial at 2-8 C, protected from light. Copper peptides are light-sensitive; keep in outer carton.
Regulatory StatusNeither component is authorised as a medicine in the UK, EU or US. Fixed combinations may attract additional regulatory scrutiny in some jurisdictions. Supplied only through appropriate professional channels.